Idiopathic Inflammatory Myopathy
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Cabaletta BioPHILADELPHIA, PA
1 program1
CABA-201 following preconditioning with fludarabine and cyclophosphamidePhase 2/31 trial
Active Trials
Alliance PharmaceuticalsUK - Wiltshire
1 programA Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory MyopathyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Cabaletta BioCABA-201 following preconditioning with fludarabine and cyclophosphamide
Alliance PharmaceuticalsA Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Clinical Trials (2)
Total enrollment: 104 patients across 2 trials
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Start: Dec 2023Est. completion: Jul 202874 patients
Phase 2/3Recruiting
NCT00971828Alliance PharmaceuticalsA Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Start: Jul 2011Est. completion: Sep 201230 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 104 patients
2 companies competing in this space